Encore Research

Call us: 904.730.0166

We have several new feathers in our cap! 

Next Science,  a Jacksonville-based research and development company contracted with JCCR to evaluate a new facial acne treatment gel.  Research physician, Susan Greco, MD wrote the research protocol and led our research teams to conduct the trial, which included designing the computer program to complete the data collection. The acne study was successfully completed at three sites - St. Johns, University and Fleming Island - on time and on budget!

Speaking of St. Johns Center for Clinical Research…. Lori Alexander, site manager of SJCCR, is currently serving as President of the Southeast Lipid Association. Although Lori has been active with SELA for many years, this is her first stint as President and most recently was featured in the winter issue of LipidSpin, the official publication of the National Lipid Association. Kudos to Lori

 JCCR’s In-patient research team, led by Dianne Gregory, was selected by Universal Biosensors, an Australian-based medical diagnostics company, as the single global site to evaluate a new point-of-care device for individuals undergoing heart catheterization. 

Another feather in our cap is that Dr. Paul Hellstern, Kim Siddell, and the Nature Coast Clinical Research team are being recognized for their success in a currently enrolling Crohn’s disease trial. Not only were they the first to enroll subjects in the trial, they are the global leader!


Posted by Amy Autry Bush Monday, May 4, 2015 9:46:00 AM Categories: Breakthroughs


(It's not the Ritz-Carlton, but it won't cost you an arm and a leg either....)

“Doing our part” for clinical research involves a number of different types of evaluations. One of the most interesting elements of research involves a Phase I evaluation. In this phase of research, patients have the opportunity to work closely with staff and physicians to determine whether a new product or therapy fits a specific medical condition. For patients, these programs generally offer a higher rate of compensation.

JCCR proudly announces that we have been selected as a Phase I research site for several state-of-the-art treatments for congestive heart failure and multiple sclerosis.

Please contact us if you or someone you know would qualify to participate in one of our Phase I programs and become a part of a possible future breakthrough!

Posted by Amy Autry Bush Thursday, January 22, 2015 11:05:00 AM Categories: Breakthroughs
Page 3 of 6 << < 1 2 3 4 5 6 > >>